Shots:

• NMPA has approved Halpryza for patients with DLBCL- FL- and CLL in China. The biosimilar is the fourth mAb approved in China following the approval of Tyvyt (biosimilar- sintilimab)- Byvasda (biosimilar- bevacizumab) and Sulinno (biosimilar- adalimumab)
• The clinical efficacy and safety of rituximab in CD20 +ve NHL have been confirmed in multiple large-scale clinical trials. Rituximab has received its FDA’s approval in 1997 for NHL- CLL- RA- GPA- MPA and PV
• The approval of Halpryza will bring a new option to Chinese Lymphoma patients- help them to improve QoL & prolong their survival. Halprryza is rituximab injection and a recombinant human/murine chimeric mAb targeting CD20 antigen on the surface of B lymphocytes and mediates CDC and ADCC
  
   ­ Ref: PRNewswire | Image: Innovent